Table 3.
Clinical trials based on PLK1 inhibition combination therapy.
| NCT number | Phase | Disease | PLK1i | Other therapy | Ref |
|---|---|---|---|---|---|
| NCT02003573 | I | acute myeloid leukemia | volasertib | escalating doses of decitabine | (176) |
| NCT00804856 | II | acute myeloid leukemia | volasertib | LDAC* | (177) |
| NCT01721876 | III | acute myeloid leukemia | volasertib | LDAC | (178) |
| NCT03303339 | I | acute myeloid leukemia | onvansertib | LDAC/decitabine | (179) |
| NCT00824408 | I | NSCLC | volasertib | pemetrexed | (133) |
| NCT01206816 | I | solid advanced tumors | volasertib | afatinib | (180) |
| NCT01022853 | I | advanced metastatic solid tumors | volasertib | nintedanib | (181) |
| NCT01772563 | I | advanced metastatic solid tumors | volasertib | itraconazole | (182) |
*low dose cytarabine